EQS-News: Stanford University Study Finds PSWT Provides Sustained Pain Relief for One of the Most Common Forms of Hand Arthritis

FREDERICK, MD - October 7, 2025 (NEWMEDIAWIRE) - BioElectronics Corporation (https://www.bielcorp.com/) (OTC: BIEL), a developer of medical technology products, announces completion and publication of a double-blind, randomized controlled clinical trial has shown that pulsed shortwave therapy (PSWT) provides sustained pain relief in adults with thumb carpometacarpal (CMC) joint osteoarthritis.  The study was conducted by researchers at Stanford University. The study abstract can be viewed here https://journals.sagepub.com/doi/10.1177/15589447251371088

Thumb arthritis is one of the most common - and painful - forms of hand arthritis. It makes everyday tasks like turning doorknobs, buttoning a shirt, or opening a jar difficult. Current treatment options are limited, often involving splints, medications, or injections. This research suggests PSWT could be a safe, drug-free option that people can use at home - potentially changing how we treat this widespread condition for the estimated 4-7 million U.S. adults with symptomatic thumb CMC arthritis.

The study, involving 61 adults with clinically and/or radiographically diagnosed thumb CMC osteoarthritis, compared outcomes between participants using an active PSWT device and those using an identical-appearing sham device. Both groups wore their devices for approximately eight hours each night over a four-week period.

At four weeks, both groups reported meaningful reductions in pain, likely influenced by the splint-like stiffness of the devices and potential placebo effects. However, after device use was discontinued, thereby removing the splinting and placebo effects, only the PSWT group maintained its pain relief by week six. The difference in pain reduction between PSWT and sham groups at this point was highly statistically significant with a p value of .02.

Other measures - including maximum pain, hand function (PRWHE), and single-assessment scores (SANE) - improved in both groups during the treatment period.

Importantly, PSWT was found to be safe and well tolerated. Adverse events were infrequent and mild, most commonly minor skin irritation from the adhesive tape. No serious adverse events occurred.

Key findings:

• Both PSWT and sham groups experienced pain reduction at 4 weeks.
• At 6 weeks, only the PSWT group sustained improvement, resulting in a significant difference versus sham.
• Benefits were not solely explained by splinting effects, placebo response, or continued device use.
• PSWT was safe, with no serious adverse events reported.

“These findings suggest that PSWT may offer a true sustained analgesic benefit for thumb osteoarthritis,” said the study investigators.

About Pulsed Shortwave Therapy (PSWT)

PSWT is a non-invasive electromagnetic therapy designed to reduce pain and improve quality of life in patients with chronic musculoskeletal conditions. Unlike medications, PSWT has no systemic side effects and can be self-administered at home.  BioElectronics' flagship product, ActiPatch, is available over-the-counter and costs less than a nickle per hour of use- an affordable, effective, drug-free solution to arthritis pain. 

About BioElectronics Corporation

BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; RecoveryRx Veterinary for animal pain. For more information, please visit www.bielcorp.com

Certain information set forth in this release contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company’s current customer, supplier and other material agreements; and (viii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. 

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. 

Although forward-looking statements contained in this release are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. 

Contact:
IR@bielcorp.com

View the original release on www.newmediawire.com